Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaFrontiers has acquired an exclusive worldwide license for the intellectual property rights and research results of an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences.
Subscribe to our email newsletter
The Shanghai Institutes for Biological Sciences (SIBS) initial human clinical trial results indicate that T cell vaccination induces immune responses that correlate with reductions in joint swelling, tenderness, pain and disability.
Pursuant to the license agreement, in exchange for an initial payment and a running royalty on the sale of commercialized products, PharmaFrontiers receives the exclusive license and all information and data related to the SIBS’ clinical trials involving the T cell vaccine.
The US Centers for Disease Control estimates that more than two million adults in the US have rheumatoid arthritis, an autoimmune disease.
“We are very excited by this research and we believe that this therapeutic T cell vaccination approach holds great promise for patients suffering from rheumatoid arthritis,” said David McWilliams, CEO of PharmaFrontiers.